Zabofloxacin

Drug Profile

Zabofloxacin

Alternative Names: DW-224a; DW224aa; PB-101; Zabofloxacin hydrochloride; Zabolante; Zrumgil

Latest Information Update: 30 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dong Wha
  • Developer Dong Wha Pharmaceutical; IASO Pharma
  • Class Antibacterials; Carboxylic acids; Cyclopropanes; Fluoroquinolones; Naphthyridines; Small molecules
  • Mechanism of Action DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Respiratory tract infections
  • No development reported Community-acquired pneumonia

Most Recent Events

  • 09 Sep 2015 No recent reports on development identified - Phase-II for Community-acquired pneumonia in South Korea (PO, capsule)
  • 01 Aug 2014 Dong Wha completes a phase III trial in Respiratory tract infections in South Korea (NCT01658020) (PO, tablet)
  • 31 Jul 2014 Dong Wha Pharmaceutical initiates enrolment in a phase I trial in Healthy volunteers in South Korea (NCT02212795)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top